Fintech

How new technologies are empowering financial advisers

From artificial intelligence to analytics advances, fintech is changing the wealth management industry. Pexels

Today's technologies have changed the wealth management industry by providing innovative tools to help empower clients and may allow a more productive and beneficial working relationship between financial advisers and their clients. Whether someone is saving for retirement, college, a new business, or travel, I have found that with new technologies, I am better able to communicate with my clients and help them meet their holistic investment goals.

It is an exciting time for wealth management. The industry is on the cutting edge of creating and adopting new technologies and innovations to empower financial advisers to engage and manage our clients' assets. Technologies such as artificial intelligence and risk analytics can provide financial advisers with a more complete picture of their clients' financial lives, which in turn helps us monitor progress and adjust course as needed.

Clients want a trusted adviser to guide them in meeting their financial goals, and now I am able to implement new technologies that help me provide a higher level of service. Using new platforms, I am able to provide real-time information and advice to my clients. I can use this technology to tailor information to their specific investments, how the market is affecting them, and determine what moves to recommend to help them get them closer to their financial goals.

With recent volatility in the market, having immediate, real-time information helps me to change direction within a client's portfolio if needed, and has been a true blessing. The risk analytics platform enables me to identify financial risks that my clients may be exposed to and allows us to quickly change course if necessary. It's a powerful way to engage. Communicating expeditiously and efficiently is important with all clients including those that have large, diversified portfolios.

Lastly, as some clients mature in age, I have begun working with them and their adult children. Together, we use technology applications to monitor the portfolio's progress to meeting the client's goals. The technological tools available within the wealth management industry have become a beneficial way to conduct business with these younger generations, especially Millennials.

As the world continues to incorporate additional technologies into all facets of life, the new tools available to wealth managers can be impactful. We can improve our relationships with clients, provide dependable information, and help guide their decisions so they may achieve their goals in life.

------

Margo Geddie is senior vice president and financial adviser with the wealth management division of Morgan Stanley in Houston.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted